Branded GLP-1 comparison guide

Wegovy vs Zepbound: how to compare branded weight-loss injections online

Compare Wegovy and Zepbound by active ingredient, FDA-labeled uses, average weight-loss evidence, sleep-apnea and cardiovascular considerations, cost, side effects, and clinician-review questions.

Comparison path

1

Confirm the exact goal: weight management, type 2 diabetes context, cardiovascular-risk reduction, obesity-related sleep apnea, MASH/liver-fibrosis questions, or another clinician-reviewed reason.

2

Match the brand to the active ingredient: Wegovy is semaglutide, while Zepbound is tirzepatide, a dual GIP and GLP-1 receptor agonist.

3

Compare eligibility before cost: BMI, weight-related conditions, prior GLP-1 response, side effects, pregnancy plans, diabetes medications, gallbladder or pancreatitis history, kidney risk, and GI disease all matter.

4

Ask how online care handles coverage, cash-pay access, prescription transfers, pharmacy availability, refill timing, storage, shipping, and follow-up.

5

Avoid sellers that blur branded and compounded status, skip prescriptions, use research-use vials, promise a specific weight-loss number, or provide switch charts without clinician review.

Direct answer

Wegovy is branded semaglutide; Zepbound is branded tirzepatide. Both are once-weekly prescription injections for chronic weight management in eligible patients. Zepbound often shows larger average weight loss and has an obesity-related sleep-apnea indication, while Wegovy has cardiovascular-risk and MASH-related labeling. The safer choice depends on diagnosis, coverage, side effects, contraindications, and clinician judgment.

Active ingredient

What is the main difference between Wegovy and Zepbound?

Wegovy contains semaglutide, a GLP-1 receptor agonist. Zepbound contains tirzepatide, which activates GIP and GLP-1 receptors. Both slow gastric emptying and affect appetite pathways, but they are not interchangeable products. A clinician should compare the exact indication, medical history, side-effect pattern, insurance coverage, and pharmacy availability before recommending one over the other.

  • Wegovy is a branded, FDA-approved semaglutide injection with weight-management labeling and additional labeled uses in selected adults.
  • Zepbound is a branded, FDA-approved tirzepatide injection for chronic weight management and moderate-to-severe obstructive sleep apnea in adults with obesity.
  • Compounded semaglutide or tirzepatide may be discussed separately when clinically appropriate, but compounded preparations are not FDA-approved finished drug products.

Expected results

Which usually leads to more weight loss?

Across major obesity studies and real-world comparisons, tirzepatide often produces greater average weight loss than semaglutide. That does not make Zepbound automatically better for every patient. A smaller, better-tolerated response with Wegovy may be preferable for some people, while others may discuss Zepbound when average weight-loss potential, sleep-apnea labeling, or prior semaglutide response matters.

  • Average study results should not be treated as a personal guarantee; dose, tolerability, nutrition, activity, follow-up, and adherence change outcomes.
  • Wegovy may be especially relevant when established cardiovascular disease, labeled cardiovascular-risk reduction, or semaglutide experience matters.
  • Zepbound may be especially relevant when clinicians are considering tirzepatide response, higher average weight-loss potential, or obesity-related sleep-apnea treatment.

Online access

How should patients compare online clinics for branded GLP-1 care?

A responsible online clinic should identify whether it is discussing branded Wegovy or Zepbound, compounded alternatives, or another medication entirely. Patients should know whether the care model includes intake, clinician review, prescription decision-making, prior authorization support when available, pharmacy coordination, side-effect guidance, refill review, and a plan for missed doses or switching.

  • Ask whether the quoted cost includes clinician review, medication, supplies if needed, shipping, refill support, and follow-up messaging.
  • Ask how nausea, vomiting, diarrhea, constipation, reflux, dehydration, gallbladder symptoms, pancreatitis warning signs, pregnancy plans, and diabetes medicines are reviewed.
  • Ask whether any switch from Wegovy to Zepbound, or Zepbound to Wegovy, requires individualized prescribing rather than a generic online conversion chart.

Patient safety checklist

Questions to ask before choosing Wegovy or Zepbound online

These points are educational and do not replace medical advice. A licensed clinician should review individual history, medications, risks, and state-specific availability before treatment.

✓

Is the recommended product Wegovy, Zepbound, Ozempic, Mounjaro, compounded semaglutide, compounded tirzepatide, or something else?

✓

Which labeled use or clinician-reviewed goal applies to me: chronic weight management, cardiovascular-risk reduction, obesity-related sleep apnea, MASH, diabetes context, or another reason?

✓

Do I have a personal or family history of medullary thyroid carcinoma, MEN2, pancreatitis, gallbladder disease, kidney disease, severe GI disease, diabetic retinopathy, pregnancy plans, or breastfeeding questions?

✓

Am I using insulin, sulfonylureas, oral contraceptives, blood-pressure medicines, psychiatric medicines, supplements, or other drugs that should be reviewed?

✓

What symptoms should prompt a message, same-day guidance, urgent care, a dose hold, or a medication change rather than self-adjusting?

✓

How are insurance, prior authorization, cash-pay options, branded supply, pharmacy transfer, storage, shipping, and refill timing handled?

✓

If I already used semaglutide or tirzepatide, who reviews side effects, response, timing, starting dose, and monitoring before a switch?

✓

Does the seller avoid guaranteed-result claims, research-use products, salt forms, no-prescription GLP-1s, and unclear compounded-versus-branded language?

FAQs

Short answers for patients

Is Zepbound stronger than Wegovy?

Zepbound has shown greater average weight loss than semaglutide in several studies and comparisons, but “stronger” is not the same as “best.” The better fit depends on indication, tolerability, contraindications, coverage, cost, prior response, and clinician judgment.

Are Wegovy and Zepbound both GLP-1 medications?

Wegovy is a GLP-1 receptor agonist. Zepbound is commonly discussed in GLP-1 care, but technically it is a dual GIP and GLP-1 receptor agonist. Patients should compare the exact product, active ingredient, and labeled use.

Does Wegovy or Zepbound have more FDA-approved uses?

They have different labeling. Wegovy is labeled for weight reduction and long-term maintenance in eligible adults and adolescents, cardiovascular-risk reduction in selected adults with established cardiovascular disease and overweight or obesity, and MASH with fibrosis under accelerated approval. Zepbound is labeled for adult weight management and moderate-to-severe obstructive sleep apnea in adults with obesity.

Can I switch from Wegovy to Zepbound online?

Possibly, but switching should be individualized by a licensed prescriber. Prior dose, timing, side effects, weight-loss response, diabetes medicines, pregnancy plans, kidney or gallbladder symptoms, and insurance or pharmacy access can change the safest plan.

Are compounded semaglutide and tirzepatide the same as Wegovy and Zepbound?

No. Wegovy and Zepbound are FDA-approved brand-name products for specific labeled uses. Compounded semaglutide or tirzepatide may be prescribed for an individual patient when clinically appropriate, but compounded preparations are not FDA-approved finished drug products.

Which costs less, Wegovy or Zepbound?

Cost depends on insurance coverage, prior authorization, cash-pay programs, pharmacy supply, dose, care model, and whether compounded alternatives are clinically appropriate. Compare the total care model, not just a headline monthly price.

Sources and related reading

Peptide12 pages use conservative educational language and authoritative sources where possible.

DailyMed: Wegovy (semaglutide) prescribing informationDailyMed: Zepbound (tirzepatide) prescribing informationJAMA Internal Medicine: Semaglutide vs tirzepatide for weight loss in adults with overweight or obesityNEJM: Once-weekly semaglutide in adults with overweight or obesityNEJM: Tirzepatide once weekly for the treatment of obesityFDA: FDA's concerns with unapproved GLP-1 drugs used for weight lossPeptide12: WegovyPeptide12: ZepboundPeptide12: Compounded semaglutide injectionPeptide12: Compounded tirzepatide injectionPeptide12: Semaglutide vs tirzepatide guidePeptide12: GLP-1 medications vs peptide therapyPeptide12: GLP-1 nausea and vomitingPeptide12: How online peptide therapy works